Evidence map›Paper›PMID 40065361›Full record

ArticleRespiratory research2025

High level of initial Aspergillus fumigatus-specific IgE links increased risk of exacerbation in allergic bronchopulmonary aspergillosis patients.

Hao Qian, Jia-Yan Xu, Rui Fan, Jing Shi, Hai-Wen Lu, Ling Ye, Jia-Wei Yang, Rui Jiang, Li-Sha Zhang, Yi-Fan Wu and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Describing the burden and characteristics ofBMJ open respiratory research · 2026
    Article
  2. Trans-Kingdom dsRNA Sensing:bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. High total serum IgE level at diagnosis was associated with a progressive decline in lung function in asthmatic patients with allergic bronchopulmonary mycosis.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hao Qian *Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Jia-Yan Xu *Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Rui Fan *Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Jing Shi *Department of Allergy, Zhongshan Hospital, Fudan University, Shanghai, China.
Hai-Wen LuDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Ling YeDepartment of Allergy, Zhongshan Hospital, Fudan University, Shanghai, China.
Jia-Wei YangDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Rui JiangDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Li-Sha ZhangDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Yi-Fan WuDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China.
Mei-Ling JinDepartment of Allergy, Zhongshan Hospital, Fudan University, Shanghai, China. jin.meiling@zs-hospital.sh.cn.
Jin-Fu XuDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Institute of Respiratory Medicine, School of Medicine, Tongji University, Shanghai, China. jfxucn@163.com.

Funding

Medical Research Project of Jiangsu Provincial Health Commission M2022101Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0522400Program of Shanghai Municipal Science and Technology Commission 21DZ2201800the Innovation Program of Shanghai Municipal Education Commission 202101070007-E00097the National Natural Science Foundation of China 81925001the National Natural Science Foundation of China 82100055the National Natural Science Foundation of China 82330070
6 · The paper itself

Abstract

backgroundElevated Aspergillus fumigatus (A. fumigatus)-specific Immunoglobulin E (IgE) is recognized as an essential diagnostic criterion for allergic bronchopulmonary aspergillosis (ABPA). However, it remains unknown whether initial A. fumigatus-specific IgE at acute stage has a role beyond diagnostic purposes.

methodThis two-center retrospective study enrolled 149 acute ABPA patients. Risk factors for one-year exacerbation were analyzed using univariate and multivariate logistic regression. Participants were then divided into a discovery cohort (n = 93) to determine the optimal initial A. fumigatus-specific IgE cut-off value via receiver operating characteristic (ROC) curve, and a validation cohort (n = 56) to confirm exacerbation differences based on this cut-off value.

resultMultivariate logistic regression analysis revealed that female sex (odds ratio (OR) 2.44, 95% confidence interval (CI) 1.15-5.16, P = 0.020), A. fumigatus-specific IgE (OR 1.05, 95% CI 1.02-1.08, P = 0.002), and bronchiectasis (OR 3.61, 95% CI 1.07-12.21, P = 0.039) were independent risk factors for ABPA exacerbation. In the discovery cohort, the optimal initial cut-off value for A. fumigatus-specific IgE was calculated to be 9.88 kUA/L. And, the validation cohort confirmed that patients with A. fumigatus-specific IgE > 9.88 kUA/L were at higher risk of exacerbation (P = 0.005).

conclusionThis study highlighted the prognostic utility of initial A. fumigatus-specific IgE at acute stage and found that elevated levels, especially those exceeding 9.88 kUA/L, were associated with increased risks of exacerbation in ABPA patients.

Indexed as

Aspergillosis, Allergic BronchopulmonaryAspergillus fumigatusDisease ProgressionImmunoglobulin EAdultAgedBiomarkersCohort StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsBiomarkersImmunoglobulin EAllergic bronchopulmonary aspergillosisAspergillus fumigatus-specific IgEExacerbationPrognostic indicator

Identifiers

PMID40065361
PMCPMC11895152

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.